109P - Impact of FDG PET-CT in response evaluation of different molecular subtypes of locally advanced breast cancers post dose dense neoadjuvant chemothe...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer Agents
Breast Cancer, Locally Advanced
Staging Procedures (clinical staging)
Pathology/Molecular Biology
Presenter Lohith Reddy
Citation Annals of Oncology (2016) 27 (suppl_9): ix30-ix34. 10.1093/annonc/mdw576
Authors L.G. Reddy1, S. P.s1, K. Kumarswamy2, K.G. Kallur2, R. Ragavendra3, A.B.S. Kumar2
  • 1Radiation Oncology, HCG Bangalore Institute of Oncology Speciality Centre, 560027 - Bangalore/IN
  • 2Radiation Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bangalore/IN
  • 3Statistics, HCG Bangalore Institute of Oncology Speciality Centre, Bangalore/IN



Irrespective of molecular subtypes neoadjuvant chemotherapy has been a preferred initial component of multi-modality treatment for locally advanced breast cancer patients. Over the last decade very few studies have been conducted to study the value of 18F-FDG PET-CT (Positive emission tomography and computed tomography) in response evaluation post neo adjuvant chemotherapy and linking it to molecular subtypes. In this study we tried to evaluate the predictive capacity of PET-CT for histopathological response post neo adjuvant therapy and linking it with molecular subtypes of breast cancer based on ER (Estrogen receptor), PR(Progesterone receptor), HER-2 (Human Epidermal Growth factor-2) and KI-67 status.


30 patients of stage II&III breast cancer patients who received dose dense doxorubicin/cyclophospomide (2weeklyx4 cycles) and paclitaxel (weeklyx 12 cycles) based neoadjuvant chemotherapy were enrolled for the prospective study from 2015 to 2016.FDG PET/CTs were acquired at diagnosis & after completion of chemotherapy prior to surgical intervention for evaluation of metabolic response (Standard uptake values- SUVs) and relating the same with molecular subtypes (Luminal A{ER+, PR+, KI-67-< or equal to 14%), Luminal B {ER+, PR+, KI-67->14%}, Luminal Her-2Neu{ER+, PR+, Her-2 neu+}, Her-2 neu Enriched{ER-, PR-, Her-2neu+}, Basal{ER-, PR-, Her-2 neu} using chi-square test for propotions.


The mean age of the sample was 50.9 years. Overall complete response was seen in 51.6% and partial response was seen in 48.4% following neoadjuvant chemotherapy when co-related with the SUVs of the PET-CTs and histopathological reports post-surgery. Complete response was maximum in basal types (75%), followed by luminal B (55.6%), Luminal A (50%), Her 2 enriched(40%) and Luminal Her2 (28.6%) though the distribution of proportions was not significant.


Results suggest that PET-CT forms an important component of evaluation prior to neoadjuvant chemotherapy to assess responses. Molecular subtypes of breast cancer differ in their responses to dose dense neoadjuvant chemotherapy.

Clinical trial indentification


Legal entity responsible for the study

Healthcare Global Enterprises


Healthcare Global Enterprises Ltd


All authors have declared no conflicts of interest.